


10 / 502,538 EAST

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	682	((514/266.2) or (514/266.4)).CCLS.	US-PGPUB; USPAT	OR	OFF	2005/12/20 16:15
L2	1145	((544/284) or (544/292)).CCLS.	US-PGPUB; USPAT	OR	OFF	2005/12/20 16:15
L3	1499	L1 or L2	US-PGPUB; USPAT	OR	OFF	2005/12/20 16:15
L4	2094	pyrrolo and (pyridin or pyridinyl or pyridyl)	US-PGPUB; USPAT	OR	OFF	2005/12/20 16:17
L5	977	L4 and (halogenation or bromination or oxidation)	US-PGPUB; USPAT	OR	OFF	2005/12/20 16:18



# STIC Search Report

## Biotech-Chem Library

STIC Database Tracking Number: 174089

TO: Tamthom Truong  
Location: REM-5C18  
Art Unit: 1624  
Tuesday, December 20, 2005

Case Serial Number: 10/502538

From: Mary Hale  
Location: Biotech/Chem Library  
Rem 1D86  
Phone: 2-2507

Mary.Hale@uspto.gov


### Search Notes

Feel free to contact me if you have any questions.

Note -- results are printed on both sides of printout

Page 1


=> d 19 que stat;fil caplus;s 19  
L5 STR



VAR G1=O/S  
VAR G2=N/CH  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 20


STEREO ATTRIBUTES: NONE  
L6 STR



VAR G1=O/S  
VAR G2=N/CH  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE  
L7 STR



Page 2

VAR G1=O/S  
VAR G2=N/CH  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE  
L9 114 SEA FILE=REGISTRY SSS FUL L7 OR L6 OR L5

100.0% PROCESSED 411 ITERATIONS 114 ANSWERS  
SEARCH TIME: 00.00.01

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	333.54	333.75

FILE 'CAPLUS' ENTERED AT 11:49:01 ON 20 DEC 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Dec 2005 VOL 143 ISS 26  
FILE LAST UPDATED: 19 Dec 2005 (20051219/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

L10 6 L9

=> d 1-6 ibib abs hitstr;fil reg


L10 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2005:1123776 CAPLUS  
DOCUMENT NUMBER: 143:405917  
TITLE: Preparation of quinazoline derivatives as protein kinase inhibitors  
INVENTOR(S): Liang, Congxin  
PATENT ASSIGNEE(S): The Scripps Research Institute, USA  
SOURCE: PCT Int. Appl., 56 pp.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097137	A2	20051020	WO 2005-US10974	20050331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2004-558025P P 20040331  
 OTHER SOURCE(S): MARPAT 143:405917  
 GI



AB The title quinazoline derivs. I [wherein X = N or (un)substituted CH; Y = O or (un)substituted NH; Z = (un)substituted Ph, pyridinyl, indolyl, etc.; R1 = H, alkyl, alkoxy, cycloalkoxy, or heterocycloalkoxy; R2 = OH, alkoxy, cycloalkoxy, or (un)substituted NH2; n = 1 or 2] or pharmaceutically acceptable salts thereof were prepared as inhibitors of protein kinases. For example, the compound II•Na was prepared in a multi-step synthesis in good yield. I are useful in treating disorders related to abnormal protein kinase activities such as cancer (no data).

IT 867146-13-2P 867146-14-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of quinazoline derivs. as protein kinase inhibitors)

RN 867146-13-2 CAPLUS

CN D-erythro-Hexonic acid, 2,4-dideoxy-6-O-[4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 867146-14-3 CAPLUS

CN D-erythro-Hexonic acid, 2,4-dideoxy-6-O-[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:1123773 CAPLUS

DOCUMENT NUMBER: 143:405916

TITLE: Preparation of quinazoline derivatives as protein kinase inhibitors

INVENTOR(S): Liang, Congxin

PATENT ASSIGNEE(S): The Scripps Research Institute, USA

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097134	A2	20051020	WO 2005-US10968	20050331

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:


US 2004-558025P

P 20040331

OTHER SOURCE(S):

MARPAT 143:405916

GI



AB The title quinazoline derivs. I [wherein X = N or (un)substituted CH; Y = O or (un)substituted NH; Z = (un)substituted Ph, pyridinyl, indolyl, etc.; R1 = H, alkyl, alkoxy, cycloalkoxy, or heterocycloalkoxy; R2 = OH, alkoxy, cycloalkoxy, or (un)substituted NH2; n = 1 or 2] or pharmaceutically acceptable salts thereof were prepared as inhibitors of protein kinases. For example, the compound II•Na was prepared in a multi-step synthesis in good yield. I are useful in treating disorders related to abnormal protein kinase activities such as cancer (no data).

IT 867146-13-2P 867146-14-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of quinazoline derivs. as protein kinase inhibitors)

RN 867146-13-2 CAPLUS

CN D-erythro-Hexonic acid, 2,4-dideoxy-6-O-[4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 867146-14-3 CAPLUS

CN D-erythro-Hexonic acid, 2,4-dideoxy-6-O-[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:141059 CAPLUS

DOCUMENT NUMBER: 142:240453

TITLE: Preparation of quinazolines as inhibitors of VEGF receptor tyrosine kinases

INVENTOR(S): Hennequin, Laurent Francois Andre

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 124 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014582	A1	20050217	WO 2004-GB3376	20040805
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,			



TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

PRIORITY APPLN. INFO.:



GB 2003-18422

A 20030806

OTHER SOURCE(S):

MARPAT 142:240453

GI



AB Title compds. I [wherein A = 8, 9, 10, 12, or 13-membered bicyclic or tricyclic (un)saturated (non)aromatic; Z = O, NH, S; n = 0-5; m = 0-3; R2 = each

independently H, OH, halo, CN, NO2, CF3, alkyl, alkoxy, etc.; R1 = each independently H, Me, F; and their salts] were prepared for the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm blooded animals. Thus, II was prepared by O-alkylation of 2,3-dimethyl-5-hydroxyindole with 4-chloro-7-(2-chloroethoxy)-6-methoxyquinazoline (preparation given), and amination of the chloride with 1-(acetylmethyl)piperazine. I inhibited gene flt-1 and KDR VEGF receptor tyrosine kinase, FGF, and EGFR receptor with IC50 values < 5  $\mu$ M in an in vivo test. I inhibited the growth factor--stimulated proliferation of HUVEC cells with IC50 values in the range of 0.001 - 5  $\mu$ M. II displayed an IC50 = 10.1  $\mu$ M in an hERG-encoded potassium channel inhibition test. I and their pharmaceutically acceptable salts are useful for treating disease states associated with angiogenesis and/or increased vascular permeability, for e.g. cancer and rheumatoid arthritis.

IT 844659-27-4P, 7-[[1-(Acetylmethyl)piperidin-4-yl]methoxy]-6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]quinazoline 844659-40-1P, 6-Methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[[1-[(pyrrolidin-1-


yl)acetyl]piperidin-4-yl]methoxy]quinazoline 844659-60-5P,  
6-Methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[2-(tetrahydro-5H-  
[1,3]dioxolo[4,5-c]pyrrol-5-yl)ethoxy]quinazoline 844659-74-1P,  
7-[2-[4-(Acetylmethyl)piperazin-1-yl]ethoxy]-6-methoxy-4-[(3-methyl-1H-  
indol-5-yl)oxy]quinazoline

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(angiogenesis inhibitor; preparation of quinazolines as inhibitors of VEGF  
receptor tyrosine kinases and their use for treating angiogenesis  
and/or increased vascular permeability)


RN 844659-27-4 CAPLUS

CN 2-Propanone, 1-[4-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-  
quinazolinyl]oxy]methyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 844659-40-1 CAPLUS

CN Piperidine, 4-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-  
quinazolinyl]oxy]methyl]-1-(1-pyrrolidinylacetyl)- (9CI) (CA INDEX NAME)




RN 844659-60-5 CAPLUS

CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[2-(tetrahydro-5H-  
1,3-dioxolo[4,5-c]pyrrol-5-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 844659-74-1 CAPLUS


CN 2-Propanone, 1-[4-[2-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



IT 288386-84-5P, 7-[[1-(tert-Butoxycarbonyl)piperidin-4-yl]methoxy]-6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]quinazoline 288386-90-3P, 6-Methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[(piperidin-4-yl)methoxy]quinazoline 844659-38-7P, 7-[[1-(Chloroacetyl)piperidin-4-yl]methoxy]-6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]quinazoline 844659-58-1P, 7-(2-Chloroethoxy)-6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]quinazoline  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of quinazolines as inhibitors of VEGF receptor tyrosine kinases and their use for treating angiogenesis and/or increased vascular permeability)


RN 288386-84-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 288386-90-3 CAPLUS

CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-(4-piperidinylmethoxy)- (9CI) (CA INDEX NAME)




RN 844659-38-7 CAPLUS

CN Piperidine, 1-(chloroacetyl)-4-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 844659-58-1 CAPLUS

CN Quinazoline, 7-(2-chloroethoxy)-6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:610442 CAPLUS

DOCUMENT NUMBER: 139:164806

TITLE: Preparation of quinazolines as VEGF receptor inhibitors

INVENTOR(S): Hennequin, Laurent Francois Andre

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 195 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003064413	A1	20030807	WO 2003-GB343	20030128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2473572 AA 20030807 CA 2003-2473572 20030128  
 EP 1474420 A1 20041110 EP 2003-700951 20030128  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 BR 2003007151 A 20041207 BR 2003-7151 20030128  
 US 2005085465 A1 20050421 US 2003-502538 20030128  
 JP 2005522428 T2 20050728 JP 2003-564036 20030128  
 NO 2004003162 A 20040722 NO 2004-3162 20040722  
 PRIORITY APPLN. INFO.: EP 2002-290242 A 20020201  
 WO 2003-GB343 W 20030128  
 OTHER SOURCE(S): CASREACT 139:164806; MARPAT 139:164806  
 GI



AB The title compds. [I; ring C = indolyl, indazolyl or azaindolyl; Z = O, NH, S; n = 0-5; m = 0-3; R2 = H, OH, halo, etc.; R1 = H, halo, oxo, OH, etc.], useful in the manufacture of a medicament for use in the production of an

antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, were prepared and formulated. E.g., a multi-step synthesis of II, was given. The compds. I inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis (no biol. data).


IT 574745-23-6P 574745-42-9P 574745-43-0P  
 574745-46-3P 574745-49-6P 574745-50-9P  
 574745-51-0P 574745-52-1P 574745-56-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazolines as VEGF inhibitors)


RN 574745-23-6 CAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 574745-42-9 CAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-(1H-indazol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 574745-43-0 CAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 574745-46-3 CAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-(1H-indazol-5-yloxy)-7-methoxy-6-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 574745-49-6 CAPLUS

CN Piperazine, 1-acetyl-4-[[[4-[[4-fluoro-1H-indol-5-yl]oxy]-7-methoxy-6-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 574745-50-9 CAPLUS

CN Piperidine, 1-acetyl-4-[[[4-[[4-fluoro-1H-indol-5-yl]oxy]-7-methoxy-6-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 574745-51-0 CAPLUS

CN Piperidine, 1-acetyl-4-[[[4-[[4-fluoro-1H-indol-5-yl]oxy]-7-methoxy-6-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 574745-52-1 CAPLUS

CN Piperidine, 4-[[4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-quinazolinyl]oxy]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 574745-56-5 CAPLUS

CN Piperazine, 1-acetyl-4-[3-[[4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)




IT 288387-52-0

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of quinazolines as VEGF inhibitors)

RN 288387-52-0 CAPLUS

CN Quinazoline, 7-(3-bromopropoxy)-4-(1H-indol-5-yloxy)-6-methoxy- (9CI) (CA INDEX NAME)



IT 574745-80-5P 574745-81-6P 574746-03-5P


574746-04-6P 574746-05-7P 574746-06-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of quinazolines as VEGF inhibitors)


RN 574745-80-5 CAPLUS

CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-(phenylmethoxy)- (9CI) (CA INDEX NAME)







RN 574745-81-6 CAPLUS  
 CN 6-Quinazolinol, 4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy- (9CI) (CA INDEX NAME)




RN 574746-03-5 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[[[4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 574746-04-6 CAPLUS  
 CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-(4-piperidinylmethoxy)- (9CI) (CA INDEX NAME)



RN 574746-05-7 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[[4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 574746-06-8 CAPLUS  
 CN Quinazoline, 4-[[4-[(4-fluoro-1H-indol-5-yl)oxy]-7-methoxy-6-(4-piperidinyloxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2001:747609 CAPLUS  
 DOCUMENT NUMBER: 135:283196  
 TITLE: Therapeutic combinations of antihypertensive and antiangiogenic agents  
 INVENTOR(S): Curwen, Jon Owen; Ogilvie, Donald James  
 PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited  
 SOURCE: PCT Int. Appl., 40 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074360	A1	20011011	WO 2001-GB1522	20010402
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2401854	AA	20011011	CA 2001-2401854	20010402
EP 1272186	A1	20030108	EP 2001-917305	20010402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001009729	A	20030204	BR 2001-9729	20010402
JP 2003528917	T2	20030930	JP 2001-572104	20010402
EE 200200578	A	20040615	EE 2002-578	20010402
NZ 520938	A	20050826	NZ 2001-520938	20010402
ZA 2002006959	A	20031201	ZA 2002-6959	20020829
US 2003144298	A1	20030731	US 2002-240413	20021001
NO 2002004814	A	20021112	NO 2002-4814	20021004
PRIORITY APPLN. INFO.:			GB 2000-8269	A 20000405
			WO 2001-GB1522	W 20010402

OTHER SOURCE(S): MARPAT 135:283196

AB The invention concerns the use of a combination of an anti-angiogenic agent and an anti-hypertensive agent for use in the manufacture of a medicament for the treatment of a disease state associated with angiogenesis in a warm-blooded mammal, such as a human being. The invention also relates to pharmaceutical compns. comprising an anti-angiogenic agent and an anti-hypertensive agent, to kits thereof and to a method of treatment of a disease state associated with angiogenesis which comprises the administration of an effective amount of a combination of an anti-angiogenic agent and an anti-hypertensive agent to a warm-blooded animal, such as a human being. Anesthetized rats were dosed orally with 12.5 mg/kg of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline for 10 days, then they were dosed orally with 30 mg/kg captopril in addition to quinazoline compound. The increase in diastolic blood pressure was reversed by the addition of captopril.


IT 288383-15-3 288383-16-4 288383-17-5  
288383-18-6 288383-19-7 288383-24-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic combinations of antihypertensive and antiangiogenic agents)


RN 288383-15-3 CAPLUS

CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 288383-16-4 CAPLUS

CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288383-17-5 CAPLUS

CN Quinazoline, 4-[(6-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-methylpyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288383-18-6 CAPLUS


CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288383-19-7 CAPLUS  
 CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-piperidinyl)propoxy] - (9CI) (CA INDEX NAME)



RN 288383-24-4 CAPLUS  
 CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy] - (9CI) (CA INDEX NAME)





REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2000:573671 CAPLUS  
 DOCUMENT NUMBER: 133:177183  
 TITLE: Preparation of quinazoline derivatives as angiogenesis inhibitors  
 INVENTOR(S): Hennequin, Laurent Francois Andre; Ple, Patrick; Stokes, Elaine Sophie Elizabeth; Mckerrecher, Darren  
 PATENT ASSIGNEE(S): Astrazeneca UK Limited, UK; Zeneca-Pharma S.A.  
 SOURCE: PCT Int. Appl., 346 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047212	A1	20000817	WO 2000-GB373	20000208
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				

CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2362715	AA	20000817	CA 2000-2362715	20000208
EP 1154774	A1	20011121	EP 2000-902730	20000208
EP 1154774	B1	20050622		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200102314	T2	20020121	TR 2001-200102314	20000208
BR 2000008128	A	20020213	BR 2000-8128	20000208
JP 2002536414	T2	20021029	JP 2000-598164	20000208
EE 200100409	A	20021216	EE 2001-409	20000208
AU 763618	B2	20030731	AU 2000-24475	20000208
NZ 513204	A	20040430	NZ 2000-513204	20000208
TR 200500745	T2	20050523	TR 2005-200500745	20000208
NZ 530832	A	20050527	NZ 2000-530832	20000208
EP 1553097	A1	20050713	EP 2005-4285	20000208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 298237	E	20050715	AT 2000-902730	20000208
RU 2262935	C2	20051027	RU 2001-124816	20000208
ZA 2001006340	A	20021101	ZA 2001-6340	20010801
NO 2001003882	A	20011009	NO 2001-3882	20010809
NO 2005002773	A	20011009	NO 2005-2773	20050608
PRIORITY APPLN. INFO.:			EP 1999-400305	A 19990210
			EP 2000-902730	A3 20000208
			WO 2000-GB373	W 20000208

OTHER SOURCE(S): MARPAT 133:177183  
GI



AB The title compds. (I) [wherein A = an 8-, 9-, 10-, 12- or 13-membered bicyclic or tricyclic ring optionally containing 1-3 O, N, and/or S heteroatoms; Z = O, NH, S, CH<sub>2</sub>, or a bond; n = 0-5; m = 0-3; R<sub>2</sub> = H, OH, halo, CN, NO<sub>2</sub>, CF<sub>3</sub>, alkyl(sulfanyl), alkoxy, NR<sub>3</sub>N<sub>4</sub>, or R<sub>5</sub>X<sub>1</sub>; R<sub>3</sub> and R<sub>4</sub> = independently H or alkyl; X<sub>1</sub> = a bond, O, CH<sub>2</sub>, OC(O), CO, S, SO, SO<sub>2</sub>, NR<sub>6</sub>CO, CONR<sub>7</sub>, SO<sub>2</sub>R<sub>8</sub>, NR<sub>9</sub>SO<sub>2</sub>, or NR<sub>10</sub>; R<sub>5</sub> = H or (un)substituted alkyl, alkenyl, alkynyl, or heterocyclyl, etc.; R<sub>6</sub>-R<sub>10</sub> = independently H or (alkoxy)alkyl] were prepared for use in the production of an antiangiogenic


and/or vascular permeability reducing effect in warm-blooded animals. For instance, II was synthesized in a 9-step sequence starting with the cyclization of 2-amino-4-benzyloxy-5-methoxybenzamide using Gold's reagent in dioxane to form 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (84%). I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis (no data).

IT **288386-84-5P**, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-((1-(tert-butoxycarbonyl)piperidin-4-yl)methoxy)quinazoline  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(angiogenesis inhibitor; preparation of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)

RN **288386-84-5** CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **288382-30-9P**, 4-(Indol-5-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline **288382-41-2P**, 6-Methoxy-7-(3-piperidinopropoxy)-4-(6-trifluoromethylindol-5-yloxy)quinazoline **288382-45-6P**, 7-[2-(N,N-Diethylamino)ethoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline **288382-46-7P**, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(piperidin-2-yl)ethoxy]quinazoline **288382-47-8P**, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(piperidin-1-yl)ethoxy]quinazoline **288382-48-9P**, 4-(Indol-6-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline **288382-50-3P**, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline **288382-57-0P**, 4-(Indol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline **288382-58-1P**, 4-(Indol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline **288382-71-8P**, 4-(Indol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline **288382-81-0P**, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazoline **288382-82-1P**, 7-[3-(N,N-Dimethylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline **288382-83-2P**, 7-[3-(N,N-Diethylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline **288382-84-3P**, 7-[3-(1,1-Dioxothiophen-2-yl)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline **288382-85-4P**, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(4-pyridyloxy)ethoxy]quinazoline **288382-86-5P**, 4-(Indol-6-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline **288382-94-5P**, 4-(Indol-5-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline **288382-97-8P**, 4-(4-Bromoindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline **288382-99-0P**, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline

288383-00-6P, (R)-7-(2-Hydroxy-3-morpholinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-01-7P, (R)-7-(2-Hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-02-8P, (S)-7-[2-Hydroxy-3-(N,N-diisopropylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-03-9P, (S)-7-(2-Hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-04-0P, (R)-7-(2-Hydroxy-3-piperidinopropoxy)-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288383-05-1P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288383-15-3P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288383-16-4P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288383-17-5P, 4-(6-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-18-6P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-19-7P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288383-24-4P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinazoline 288383-84-6P, 6-Methoxy-4-(indol-6-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288384-08-7P, 7-Benzylloxy-4-(indol-5-yloxy)-6-methoxyquinazoline 288384-09-8P, 7-[2-(N,N-Dimethylamino)ethoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288384-10-1P, (S)-4-(Indol-5-yloxy)-6-methoxy-7-(1-methylpyrrolidin-2-yl)quinazoline 288384-11-2P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]quinazoline 288384-12-3P, 4-(Indol-6-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288384-42-9P, 4-(Indol-5-yloxy)-6-methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-63-4P, 4-(6-Methoxyindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-64-5P, 4-(Indol-4-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-75-8P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288384-76-9P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-(2-piperidinoethoxy)quinazoline 288384-78-1P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288385-86-4P, 7-[[1-(Cyanomethyl)piperidin-4-yl]methoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288386-17-4P, 4-(6-Fluoroindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288386-24-3P, 4-(6-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288386-27-6P, 4-(6-Fluoroindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288386-31-2P, 4-(6-Fluoroindol-5-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288386-32-3P, 4-(Indol-5-yloxy)-6-methoxy-7-(2-morpholinoethoxy)quinazoline 288386-33-4P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(pyrrolidin-1-yl)ethoxy]quinazoline 288386-34-5P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(4-methylpiperazin-1-yl)ethoxy]quinazoline 288386-36-7P, 4-(Indol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288386-77-6P, 7-Hydroxy-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288386-79-8P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline 288386-81-2P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-(2-morpholinoethoxy)quinazoline 288386-88-9P, 7-[3-(1,1-Dioxothiomorpholino)propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288386-90-3P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline 288386-92-5P, 7-((1-(Cyanomethyl)piperidin-4-yl)methoxy)-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288386-94-7P, (R)-6-Methoxy-4-(3-methylindol-5-yloxy)-7-(oxiran-2-ylmethoxy)quinazoline




288386-97-0P, (R)-7-[2-Hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288386-99-2P, (R)-7-(2-Hydroxy-3-morpholinopropoxy)-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288387-01-9P, (R)-7-(2-Hydroxy-3-dimethylaminopropoxy)-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288387-03-1P, (R)-7-[2-Hydroxy-3-(N,N-diethylamino)propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288387-05-3P, (R)-7-[2-Hydroxy-3-(isopropylamino)propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288387-07-5P, (R)-7-[2-Hydroxy-3-(N,N-diisopropylamino)propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288387-09-7P, (R)-7-[2-Hydroxy-3-(3-morpholinopropylamino)propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288387-11-1P, (R)-7-[2-Hydroxy-3-[(3-(4-methylpiperazin-1-yl)propyl)amino]propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288387-13-3P, (R)-7-[2-Hydroxy-3-[(3-(pyrrolidin-1-yl)propyl)amino]propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288387-19-9P, 6-Methoxy-4-(1-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline 288387-23-5P, (R)-7-(2-Hydroxy-3-dimethylaminopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288387-25-7P, (R)-7-[2-Hydroxy-3-(N,N-diisopropylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288387-29-1P, (S)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288387-31-5P, (S)-7-(2-Hydroxy-3-morpholinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288387-33-7P, (S)-7-(2-Hydroxy-3-dimethylaminopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288387-35-9P, (R)-7-(2-Hydroxy-3-(isopropylamino)propoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288387-37-1P, (S)-7-[2-Hydroxy-3-(isopropylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288387-44-0P, 6-Methoxy-4-(1-methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline 288387-45-1P, 6-Methoxy-4-(1-methylindol-5-yloxy)-7-(2-piperidinopropoxy)quinazoline 288387-46-2P, 6-Methoxy-4-(1-methylindol-5-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288387-47-3P, 6-Methoxy-4-(4-nitroindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline 288387-50-8P, 4-(4-Aminoindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288387-53-1P, 4-(Indol-5-yloxy)-6-methoxy-7-[3-(4-piperidinylpiperidino)propoxy]quinazoline 288387-57-5P, (S)-4-(1H-Indol-5-yloxy)-6-methoxy-7-[(2-oxopyrrolidin-5-yl)methoxy]quinazoline 288387-59-7P, (R)-4-(1H-Indol-5-yloxy)-6-methoxy-7-(2-oxopyrrolidin-5-ylmethoxy)quinazoline 288387-60-0P, 6-Methoxy-4-[1-(3-piperidinopropyl)-1H-indol-5-yloxy]-7-(3-piperidinopropoxy)quinazoline

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(angiogenesis inhibitor; preparation of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)


RN 288382-30-9 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[3-(methylsulfonyl)propoxy]-(9CI) (CA INDEX NAME)




RN 288382-41-2 CAPLUS

CN Quinazoline, 6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-[[6-(trifluoromethyl)-1H-indol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 288382-45-6 CAPLUS

CN Ethanamine, N,N-diethyl-2-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 288382-46-7 CAPLUS


CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(2-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 288382-47-8 CAPLUS  
 CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(1-piperidinyl)ethoxy]-(9CI) (CA INDEX NAME)



RN 288382-48-9 CAPLUS  
 CN Quinazoline, 4-(1H-indol-6-yloxy)-6-methoxy-7-[3-(4-morpholinyl)propoxy]-(9CI) (CA INDEX NAME)




RN 288382-50-3 CAPLUS  
 CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[3-(1-piperidinyl)propoxy]-(9CI) (CA INDEX NAME)




RN 288382-57-0 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 288382-58-1 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288382-71-8 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288382-81-0 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-(9CI) (CA INDEX NAME)




RN 288382-82-1 CAPLUS

CN 1-Propanamine, 3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 288382-83-2 CAPLUS

CN 1-Propanamine, N,N-diethyl-3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 288382-84-3 CAPLUS

CN Quinazoline, 7-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-4-(1H-indol-5-yloxy)-6-methoxy- (9CI) (CA INDEX NAME)




RN 288382-85-4 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(4-pyridinyloxy)ethoxy]-(9CI) (CA INDEX NAME)




RN 288382-86-5 CAPLUS

CN Quinazoline, 4-(1H-indol-6-yloxy)-6-methoxy-7-[3-(1-piperidinyloxy)propoxy]-(9CI) (CA INDEX NAME)




RN 288382-94-5 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[3-(4-morpholinyl)propoxy]-(9CI) (CA INDEX NAME)



RN 288382-97-8 CAPLUS


CN Quinazoline, 4-[(4-bromo-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288382-99-0 CAPLUS

CN 1-Pyrrolidineethanol,  $\alpha$ -[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288383-00-6 CAPLUS

CN 4-Morpholineethanol,  $\alpha$ -[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288383-01-7 CAPLUS

CN 1-Piperidineethanol,  $\alpha$ -[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy)methyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288383-02-8 CAPLUS

CN 2-Propanol, 1-[bis(1-methylethyl)amino]-3-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288383-03-9 CAPLUS

CN 1-Piperidineethanol,  $\alpha$ -[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy)methyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 288383-04-0 CAPLUS

CN 1-Piperidineethanol,  $\alpha$ -[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288383-05-1 CAPLUS


CN 1-Pyrrolidineethanol,  $\alpha$ -[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288383-15-3 CAPLUS

CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[(1-methyl-4-piperidinyloxy)methoxy]- (9CI) (CA INDEX NAME)




RN 288383-16-4 CAPLUS

CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288383-17-5 CAPLUS


CN Quinazoline, 4-[(6-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-methyl-4-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288383-18-6 CAPLUS  
 CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288383-19-7 CAPLUS  
 CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288383-24-4 CAPLUS  
 CN Quinazoline, 4-[(4-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 288383-84-6 CAPLUS

CN Quinazoline, 4-(1H-indol-6-yloxy)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-(9CI) (CA INDEX NAME)




RN 288384-08-7 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-(phenylmethoxy)-(9CI) (CA INDEX NAME)



RN 288384-09-8 CAPLUS


CN Ethanamine, 2-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-N,N-dimethyl-(9CI) (CA INDEX NAME)




RN 288384-10-1 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[(2S)-1-methyl-2-pyrrolidinyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 288384-11-2 CAPLUS  
 CN Ethanamine, N-[2-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]ethyl]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 288384-12-3 CAPLUS  
 CN Quinazoline, 4-(1H-indol-6-yloxy)-6-methoxy-7-[3-(methanesulfonyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288384-42-9 CAPLUS  
 CN Methanesulfonamide, N-[3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 288384-63-4 CAPLUS

CN Quinazoline, 6-methoxy-4-[(6-methoxy-1H-indol-5-yl)oxy]-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288384-64-5 CAPLUS

CN Quinazoline, 4-(1H-indol-4-yloxy)-6-methoxy-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288384-75-8 CAPLUS

CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288384-76-9 CAPLUS

CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 288384-78-1 CAPLUS

CN Methanesulfonamide, N-[3-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 288385-86-4 CAPLUS

CN 1-Piperidineacetonitrile, 4-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 288386-17-4 CAPLUS

CN Quinazoline, 4-[(6-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[(1-methyl-4-piperidiny)methoxy]- (9CI) (CA INDEX NAME)




RN 288386-24-3 CAPLUS

CN Quinazoline, 4-[(6-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288386-27-6 CAPLUS


CN Quinazoline, 4-[(6-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-piperidiny)propoxy]- (9CI) (CA INDEX NAME)






RN 288386-31-2 CAPLUS

CN Quinazoline, 4-[(6-fluoro-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(4-morpholinyl)propoxy] - (9CI) (CA INDEX NAME)




RN 288386-32-3 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(4-morpholinyl)ethoxy] - (9CI) (CA INDEX NAME)




RN 288386-33-4 CAPLUS

CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy] - (9CI) (CA INDEX NAME)




RN 288386-34-5 CAPLUS


CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy] - (9CI) (CA INDEX NAME)




RN 288386-36-7 CAPLUS  
 CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288386-77-6 CAPLUS  
 CN 7-Quinazolinol, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]- (9CI) (CA INDEX NAME)




RN 288386-79-8 CAPLUS  
 CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288386-81-2 CAPLUS

CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 288386-88-9 CAPLUS

CN Quinazoline, 7-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]- (9CI) (CA INDEX NAME)




RN 288386-90-3 CAPLUS

CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-(4-piperidinylmethoxy)- (9CI) (CA INDEX NAME)



RN 288386-92-5 CAPLUS


CN 1-Piperidineacetonitrile, 4-[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 288386-94-7 CAPLUS

CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-[(2R)-oxiranylmethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288386-97-0 CAPLUS

CN 1-Piperazineethanol,  $\alpha$ -[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-4-methyl-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288386-99-2 CAPLUS

CN 4-Morpholineethanol,  $\alpha$ -[[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]methyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288387-01-9 CAPLUS

CN 2-Propanol, 1-(dimethylamino)-3-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288387-03-1 CAPLUS

CN 2-Propanol, 1-(diethylamino)-3-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288387-05-3 CAPLUS

CN 2-Propanol, 1-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-3-[(1-methylethyl)amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288387-07-5 CAPLUS

CN 2-Propanol, 1-bis[(1-methylethyl)amino]-3-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288387-09-7 CAPLUS

CN 2-Propanol, 1-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-3-[[3-(4-morpholinyl)propyl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288387-11-1 CAPLUS

CN 2-Propanol, 1-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-3-[[3-(4-methyl-1-piperazinyl)propyl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288387-13-3 CAPLUS


CN 2-Propanol, 1-[[6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-quinazolinyl]oxy]-3-[[3-(1-pyrrolidinyl)propyl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-19-9 CAPLUS


CN Quinazoline, 6-methoxy-4-[(1-methyl-1H-indol-5-yl)oxy]-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 288387-23-5 CAPLUS

CN 2-Propanol, 1-(dimethylamino)-3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288387-25-7 CAPLUS

CN 2-Propanol, 1-[bis(1-methylethyl)amino]-3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-, (2R)- (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 288387-29-1 CAPLUS

CN 1-Pyrrolidineethanol,  $\alpha$ -[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288387-31-5 CAPLUS

CN 4-Morpholineethanol,  $\alpha$ -[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]methyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288387-33-7 CAPLUS

CN 2-Propanol, 1-(dimethylamino)-3-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288387-35-9 CAPLUS

CN 2-Propanol, 1-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-3-[(1-methylethyl)amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288387-37-1 CAPLUS


CN 2-Propanol, 1-[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy]-3-[(1-methylethyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288387-44-0 CAPLUS

CN Quinazoline, 6-methoxy-4-[(1-methyl-1H-indol-5-yl)oxy]-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288387-45-1 CAPLUS

CN Quinazoline, 6-methoxy-4-[(1-methyl-1H-indol-5-yl)oxy]-7-[2-(1-piperidiny)propoxy]- (9CI) (CA INDEX NAME)




RN 288387-46-2 CAPLUS

CN Quinazoline, 6-methoxy-4-[(1-methyl-1H-indol-5-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288387-47-3 CAPLUS

CN Quinazoline, 6-methoxy-4-[(4-nitro-1H-indol-5-yl)oxy]-7-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 288387-50-8 CAPLUS

CN 1H-Indol-4-amine, 5-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)



RN 288387-53-1 CAPLUS


CN Quinazoline, 7-(3-[1,4'-bipiperidin]-1'-ylpropoxy)-4-(1H-indol-5-yloxy)-6-methoxy- (9CI) (CA INDEX NAME)



RN 288387-57-5 CAPLUS

CN 2-Pyrrolidinone, 5-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy)methyl]-, (5S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 288387-59-7 CAPLUS


CN 2-Pyrrolidinone, 5-[[[4-(1H-indol-5-yloxy)-6-methoxy-7-quinazolinyl]oxy)methyl]-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288387-60-0 CAPLUS

CN Quinazoline, 6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-[[1-[3-(1-piperidinyl)propyl]-1H-indol-5-yl]oxy]- (9CI) (CA INDEX NAME)




IT	288384-07-6P, 7-Hydroxy-4-(indol-5-yloxy)-6-methoxyquinazoline
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
	(intermediate; preparation of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)
RN	288384-07-6 CAPLUS
CN	7-Quinazolinol, 4-(1H-indol-5-yloxy)-6-methoxy- (9CI) (CA INDEX NAME)



IT 288386-75-4P, 7-Benzylloxy-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288387-21-3P, (R)-4-(Indol-5-yloxy)-6-methoxy-7-(oxiran-2-ylmethoxy)quinazoline 288387-27-9P, (S)-4-(Indol-5-yloxy)-6-methoxy-7-(oxiran-2-ylmethoxy)quinazoline 288387-52-0P, 7-(3-Bromopropoxy)-4-(1H-indol-5-yloxy)-6-methoxyquinazoline  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)


RN 288386-75-4 CAPLUS

CN Quinazoline, 6-methoxy-4-[(3-methyl-1H-indol-5-yl)oxy]-7-(phenylmethoxy)-(9CI) (CA INDEX NAME)




RN 288387-21-3 CAPLUS  
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[(2R)-oxiranylmethoxy]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 288387-27-9 CAPLUS  
CN Quinazoline, 4-(1H-indol-5-yloxy)-6-methoxy-7-[(2S)-oxiranylmethoxy]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288387-52-0 CAPLUS  
CN Quinazoline, 7-(3-bromopropoxy)-4-(1H-indol-5-yloxy)-6-methoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	30.09	363.84
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.38	-4.38

FILE 'REGISTRY' ENTERED AT 11:49:45 ON 20 DEC 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 19 DEC 2005 HIGHEST RN 870234-75-6  
 DICTIONARY FILE UPDATES: 19 DEC 2005 HIGHEST RN 870234-75-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS  
 for details.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> dis his

(FILE 'HOME' ENTERED AT 11:44:07 ON 20 DEC 2005)

FILE 'REGISTRY' ENTERED AT 11:44:14 ON 20 DEC 2005

```
L1      STR
L2      STR L1
L3      STR L2
L4      0 S L1 OR L2 OR L3
L5      STR L1
L6      STR L2
L7      STR L3
L8      10 S L7 OR L6 OR L5
```


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



L9 114 S L8 FUL

FILE 'CAPLUS' ENTERED AT 11:49:01 ON 20 DEC 2005  
L10 6 S L9


=> d l9 que stat  
L5 STR



VAR G1=O/S  
VAR G2=N/CH  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 20


STEREO ATTRIBUTES: NONE  
L6 STR



VAR G1=O/S  
VAR G2=N/CH  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE  
L7 STR



VAR G1=O/S  
 VAR G2=N/CH  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE  
 L9 114 SEA FILE=REGISTRY SSS FUL L7 OR L6 OR L5

100.0% PROCESSED 411 ITERATIONS  
 SEARCH TIME: 00.00.01

114 ANSWERS

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
26.07	389.91

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-4.38

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 11:52:45 ON 20 DEC 2005